In summary, the immune profiling described here could aid in refining MDS stratification, particularly in distinguishing patients who may benefit from immune‐modulating therapies such as IRAK4 inhibitors or NF‐κB‐targeting agents. This evidence concerns the gene IRAK4 and myelodysplastic syndrome.